Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Luye Pharma Group (LUP) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ly03015Healthy ParticipantsPhase ICompletedA Study of LY03015 in Healthy Chinese and Caucasian Adult SubjectsApr 14, 2026―
Ly03017Negative Symptoms Of Schizophrenia, Hallucinations And Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations And Delusions Associated With Parkinson Disease PsychosisPhase INot Yet RecruitingA Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017May 12, 2025
Ly03017Parkinson Disease Psychosis, Alzheimer's Disease Psychosis, Negative Symptoms Of SchizophreniaPhase INot Yet RecruitingEffect of Food and Age on the Pharmacokinetics of LY03017Jan 20, 2025
Lpm3770164 Sustained Release Tablet Simulant, Lpm3770164 Sustained Release Tablet 5 Mg, Lpm3770164 Sustained Release Tablet 10 Mg, Lpm3770164 Sustained Release Tablet 20 MgTardive Dyskinesia (Td)phase1AndPhase2RecruitingSafety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive DyskinesiaDec 09, 2024
Ly03020Schizophrenia, Alzheimer's Disease PsychosisPhase ICompletedA Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy SubjectsAug 13, 2024―
Irinotecan, Topotecan, LurbinectedinRelapsed Small Cell Lung CancerPhase IIIRecruitingLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCJul 03, 2024
Lpm3770164 Sustained Release TabletTardive Dyskinesia, Huntington DiseasePhase ICompletedEffect of Food on the Pharmacokinetics of LPM3770164 Sustained-release TabletsJun 20, 2024―
Lpm3770164 Sustained Release Tablet, Lpm3770164 Sustained Release Tablet SimulantHuntington Disease, Tardive DyskinesiaPhase ICompletedSafety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy SubjectsDec 19, 2023―
Toludesvenlafaxine Hydrochloride Sustained-Release Tablet 80Mg, Toludesvenlafaxine Hydrochloride Sustained-Release Tablet 160MgGeneralized Anxiety DisorderPhase IIICompletedA Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.Jul 24, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Luye Pharma Group (DE:LUP) have in its pipeline
Luye Pharma Group DE:LUP is currently developing the following drugs: Ly03015, Ly03017, Lpm3770164 Sustained Release Tablet Simulant, Lpm3770164 Sustained Release Tablet 5 Mg, Lpm3770164 Sustained Release Tablet 10 Mg, Lpm3770164 Sustained Release Tablet 20 Mg, Ly03020, Irinotecan, Topotecan, Lurbinectedin, Lpm3770164 Sustained Release Tablet, Lpm3770164 Sustained Release Tablet, Lpm3770164 Sustained Release Tablet Simulant, Toludesvenlafaxine Hydrochloride Sustained-Release Tablet 80Mg, Toludesvenlafaxine Hydrochloride Sustained-Release Tablet 160Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.